Table 1. Baseline characteristics among treated HCV and HCV/HIV infected participants with recently acquired HCV infection and adherent to PEG-IFN therapy (n = 89).
| Overall(n = 89) n (%) | HCV infected (PEG-IFN) (n = 57) n (%) | HCV/HIV infected (PEG-IFN/ribavirin) (n = 32) n (%) | |
| Male Sex | 67 (75) | 35 (61) | 32 (100) |
| Mean age, yrs (SD) | 34.8 (10.5) | 31.0 (9.2) | 41.6 (9.4) |
| Tertiary education or greater | 47 (53) | 24 (42) | 23 (72) |
| Full-time or part-time employment | 43 (48) | 21(37) | 22 (69) |
| Injecting drug use ever | 66 (74) | 48 (84) | 18 (56) |
| Injection drug use in previous 30 days | 26 (30) | 22 (39) | 4 (13) |
| Social support | |||
| ≤14 | 52 (58) | 27 (47) | 25 (78) |
| ≥14 | 28 (31) | 23 (40) | 5 (16) |
| Missing | 9 (10) | 7 (12) | 2 (6) |
| IL28B genotype | |||
| rs8099917 | |||
| GG | 4 (5) | 1 (2) | 3 (10) |
| GT | 31 (36) | 23 (42) | 8 (26) |
| TT | 51 (59) | 31 (56) | 20 (65) |
| rs12979860 | |||
| CC | 42 (48) | 24 (43) | 18 (58) |
| CT | 36 (41) | 27 (48) | 9 (29) |
| TT | 9 (10) | 5 (9) | 4 (13) |
| Mode of HCV acquisition | |||
| Injecting drug use | 60 (67) | 48 (84) | 12 (38) |
| Sexual | 23 (26) | 4 (7) | 19 (59) |
| Other | 6 (7) | 5 (9) | 1 (3) |
| Estimated duration of HCV infection ≥26 wks* | 67 (75) | 46 (81) | 21(66) |
| Presentation of recent HCV ¥ | |||
| Acute clinical (symptomatic) | 34 (38) | 20 (35) | 14 (44) |
| Acute clinical (ALT >400 IU/mL) | 21 (24) | 11 (19) | 10 (31) |
| Asymptomatic seroconversion | 34 (38) | 26 (46) | 8 (25) |
| HCV RNA ≥400,000 IU/mL* | 36 (40) | 18 (32) | 18 (56) |
| HCV genotype | |||
| Genotype 1 | 50 (56) | 33 (58) | 17 (53) |
| Genotype 2 | 5 (6) | 1 (2) | 4 (13) |
| Genotype 3 | 33 (37) | 22 (39) | 11 (34) |
| Mixed HCV genotype 1/3 | 1 (1) | 1 (2) | 0 (0) |
*
at baseline,
¥
denominator is total number of people reporting documented illness.
SD, standard deviation.